Long-term Monitoring of Growth and Development of Pediatric Patients Previously Treated With Everolimus

Completed · Phase 4

Conditions studied: Growth and Development

In brief

The primary objective of CRAD001M2305 was to report the long-term effects of everolimus treatment on height, weight and sexual development (using Tanner Stages) in children and adolescents with Tuberous Sclerosis Complex (TSC)-associated with Subependymal Giant Cell Astrocytoma (SEGA). The study monitored the growth and development of pediatric patients with TSC-associated SEGA, previously enrolled in CRAD001M2301 (NCT00789828) until they reach Tanner Stage V, or until age 16 for females or 17 for males whichever occurred first.

Key facts

Study ID
NCT02338609
Run by
Novartis Pharmaceuticals
People needed
15
Starts
2014-12-17
Expected to finish
2023-12-18
Last updated by the study team
2024-08-09

Who can join

Age: any, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.